Systemic anticancer mechanisms and precision oncology
Connect drug class with the cellular effect
Cytotoxic classes differ in their interaction with DNA, nucleotide metabolism and the mitotic apparatus. Platinum compounds form DNA adducts and crosslinks. Taxanes stabilize microtubules, whereas vinca alkaloids interfere with assembly. Anthracyclines affect topoisomerase-mediated DNA processes and have important cardiac risks. An antimetabolite mechanism is not interchangeable with the way a rescue agent or a drug-eliminating enzyme works. Leucovorin can support rescue after methotrexate while potentiating fluorouracil through a different biochemical context. The same supporting drug name therefore does not imply the same therapeutic role.
Targets require the right molecular context
A receptor antibody, a small-molecule kinase inhibitor and an antibody-drug conjugate are distinct technologies. An antibody-drug conjugate has an antigen-binding component, linker and payload, each contributing to activity and toxicity. The named target of one T-cell engager must not be attributed to every other myeloma product. A fusion, activating mutation, amplification and variant of uncertain significance have different evidential roles. A tumor-only result does not automatically establish an inherited variant, and a negative liquid biopsy can reflect insufficient shedding rather than guaranteed absence of the alteration.
Resistance and immune response
Tumor dependence on an oncogenic pathway can explain sensitivity, but resistance can emerge through changes in the target, downstream signaling, lineage or repair pathway. A BRCA reversion can restore a functional reading frame and change treatment response. Synthetic lethality describes vulnerability when two relevant functions are jointly disrupted, not a guarantee that any vaguely related repair-gene variant predicts equal benefit. Checkpoint inhibition affects immune regulation and can produce delayed effects and toxicity. A response-assessment framework such as iRECIST has defined conditions and is not permission to continue ineffective treatment through clinical deterioration.
Exposure, calculation and eligibility
Dose assessment considers the actual agent, regimen, organ function, interactions and laboratory method. For an arithmetic example with a supplied usable GFR of 50 mL/min and target AUC of 5, the stated Calvert model gives 5 multiplied by 75, or 375 mg. This calculation does not validate an estimated renal value, choose the regimen or replace protocol-specific assessment. Drug labels and comparative evidence can change, so distinguish a demonstrated mechanism or historical trial result from an unlimited current national indication. Patient eligibility and an evidence-supported sequence remain essential even when the molecular match appears attractive.